InMode Ltd. (NASDAQ:INMD) Stock Position Lowered by Boston Trust Walden Corp

Boston Trust Walden Corp decreased its position in InMode Ltd. (NASDAQ:INMD) by 2.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,367,376 shares of the healthcare company’s stock after selling 40,695 shares during the period. Boston Trust Walden Corp’s holdings in InMode were worth $22,835,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in InMode by 221.7% in the 3rd quarter. SG Americas Securities LLC now owns 73,611 shares of the healthcare company’s stock valued at $1,248,000 after acquiring an additional 50,731 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in InMode by 6.7% during the third quarter. Handelsbanken Fonder AB now owns 128,097 shares of the healthcare company’s stock valued at $2,171,000 after purchasing an additional 8,028 shares during the last quarter. Unison Advisors LLC bought a new stake in InMode during the third quarter worth approximately $675,000. Inspire Advisors LLC grew its position in InMode by 45.5% in the third quarter. Inspire Advisors LLC now owns 31,192 shares of the healthcare company’s stock worth $529,000 after buying an additional 9,759 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of InMode by 314.7% in the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock valued at $60,000 after buying an additional 2,694 shares in the last quarter. Institutional investors own 68.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on INMD shares. BTIG Research started coverage on InMode in a report on Thursday, October 17th. They issued a “buy” rating and a $25.00 target price on the stock. Barclays cut their price objective on InMode from $27.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of InMode in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $22.40.

InMode Trading Down 3.1 %

NASDAQ:INMD opened at $16.67 on Tuesday. The business’s fifty day moving average price is $17.54 and its 200 day moving average price is $17.21. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of 9.01 and a beta of 2.13. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $26.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.